Ten weeks in, your bloodwork tells you which trajectory you're on. Three patterns emerge from the practitioner corpus, and each demands a different next move. The mistake most self-experimenters make is reading partial response as failure and bailing — or reading clear response as permission to stop. Neither is correct. NAD+ optimization is a biology problem with a feedback signal, and the feedback signal is the labs.
What the markers actually mean
The substrate is clear on which markers carry signal for NAD+ work. NAD+/NADH ratio is the headline number — it indexes cellular energy metabolism efficiency, and a depressed ratio is the cellular signature of mitochondrial dysfunction. Lactate-to-pyruvate ratio is the lagging confirmatory marker: elevated L:P ratio means redox status is still skewed, the electron transport chain is still bottlenecked, and pyruvate is being shunted to lactate because mitochondria can't accept it fast enough. CRP and hs-CRP track the inflammatory consequence of ROS leakage from damaged mitochondria — when NAD+ pools recover and electron transport tightens, ROS production at the source declines, and CRP follows. Organic Acid Testing (OAT), where available, confirms mitochondrial membrane function at the metabolite level.
Two enzymes quietly stand between you and your protocol working: CD38 and NNMT. CD38 is the NADase that catabolizes NAD+ faster than your salvage pathway can rebuild it — this is why supply-side precursors (NMN, NR) alone can underperform in older or more inflamed subjects. NNMT is the methylation enzyme that wastes NAD+ via the methyl-group sink. The compounds you brought in for Phase 2 — 5-Amino-1MQ to inhibit NNMT, and the choice of whether to inhibit CD38 — are what convert a supply-only strategy into a net-positive NAD+ balance strategy. When labs don't move, the question is almost always: which enzyme is still winning?
Reading the trajectory
Clear response. NAD+/NADH ratio improved meaningfully, lactate-to-pyruvate ratio moved toward normal, CRP trending down, subjective energy stable and improving across Weeks 5-10. This is the trajectory the protocol was designed for. Do not stack more compounds. Do not escalate doses. The next move is consolidation: drop to maintenance dosing and let the biology hold.
Partial response. Some markers moved, others didn't. Energy improved in Phase 1 but plateaued in Phase 2. CRP came down but NAD+/NADH ratio is still depressed. This is the most common pattern and the most diagnostically rich. The substrate's framing on MOTS-c partial response applies here directly: "If Phase 2 was tolerated well — energy improved, no adverse reactions" — but markers haven't fully normalized, the answer is rarely "more of the same compound." It's usually a missing lever, most often on the waste-inhibition side or the mitochondrial-membrane side.
No response. Markers unchanged or worsened despite verified compliance and reconstitution math checked. This is not a failure of NAD+ biology — it's a sign the rate-limiting step is upstream or downstream of where the current stack is acting. The substrate is explicit: if fatigue worsens during a mitochondrial protocol, "stop and extend the preparatory phase. This is not a failure — it's data."
Next-protocol by trajectory
| Trajectory | Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|---|
| Clear response — maintenance | NMN | Substrate-cited range — taper from Phase 2 dose to ~50% | SubQ or oral | Daily, 5 on / 2 off | Expert | Hold supply-side floor while CD38/NNMT pressure is lower |
| Clear response — maintenance | 5-Amino-1MQ | 50-100mg/day | Oral | Daily, cycled | Expert | Keep NNMT inhibition active; the net-positive balance depends on both sides |
| Partial response — add waste inhibition | 5-Amino-1MQ | 50-100mg/day | Oral | Daily | Expert | If not already running, this is the highest-leverage add — NMN supply without NNMT inhibition leaks methyl groups |
| Partial response — add mitochondrial membrane | SS-31 (Elamipretide) | 0.01-0.25 mg/kg (titration range from published trial protocols) | SubQ | Daily, conservative escalation | Experimental | Stabilizes cardiolipin and supercomplex architecture. Indicated when NAD+ moves but L:P ratio stays elevated — points to ETC misalignment, not precursor shortage |
| Partial response — add ATP bypass | Methylene Blue | 0.5-1mg/day (pharmaceutical dose, NOT the 10-15mg circulated online) | Oral | Morning, 5 on / 2 off, mandatory cycling | Expert | Hormetic — higher doses flip the dose-response curve. Bypasses Complex I/III bottlenecks. Assess response for 5 days before considering 1mg |
| No response — extend prep phase | BPC-157 | 500 mcg/day | SubQ | Daily, 2-4 weeks | Expert | Accelerates mitochondrial membrane repair before retrying the upstream stack. Substrate explicit: "Do not retry [the failed compound] until fatigue has fully resolved" |
| No response — confirm root cause | Retest panel | NAD+/NADH, L:P ratio, hs-CRP, CBC | Lab | Before next protocol cycle | Clinical | Without baseline, follow-up labs are meaningless numbers |
| No response — caffeine support during infusions (if doing NAD+ IV/SubQ) | Caffeine | Standard | Oral | Pre-infusion | Expert | Blocks adenosine receptors; substrate notes this reduces the sluggish/uncomfortable sensations during infusion and supports recycling pathway |
A note on injected NAD+ specifically: the substrate is skeptical. The mechanism described is that injected NAD+ is "almost certainly being degraded to nicotinamide riboside and to nicotinamide" before intracellular uptake, because the intracellular nicotinamide riboside kinases need NR, not NAD+, as substrate. If you ran a no-response trajectory on injected NAD+, the next protocol is not more NAD+ — it's a precursor (NMN or NR) plus an NNMT inhibitor. The supply-side compound matters less than the waste-inhibition pairing.
What you should feel — by trajectory
- Clear response, Weeks 11-12 (maintenance): Energy stable, no rebound fatigue when dropping to maintenance doses. Sleep architecture intact. The taper is the test — if energy holds, the biology is holding.
- Partial response, Weeks 11-14 (added lever): If 5-Amino-1MQ was the missing piece, lipolysis and energy should shift within 2-3 weeks. If SS-31 was the missing piece, the L:P ratio is the marker to watch — expect movement by week 4 of the add, not week 1.
- No response, Weeks 11-14 (prep phase): Inflammation markers should come down first. Energy may not improve during the prep phase — that's expected. The prep phase is not the protocol; it's preparing the cellular terrain for the protocol to work the second time.
What's NOT happening yet
- Partial response is not failure. The substrate frames sub-optimal Phase 2 response as a diagnostic signal, not a verdict. Two enzymes (CD38, NNMT) and one membrane (cardiolipin) explain most partial responses — work the right lever before abandoning the protocol.
- A clear response on NAD+/NADH ratio does not mean the lactate-to-pyruvate ratio has normalized. Redox lags. The L:P ratio can take an additional 4-8 weeks to follow.
- No response after one cycle does not mean the compound class doesn't work for you. Compliance issues, reconstitution math errors, and missing waste-inhibition partners account for most apparent non-responses in the practitioner corpus.
- Stacking more compounds is not the answer to partial response. Adding the right one compound is. The substrate is consistent: prepare before you push, and add levers based on which marker isn't moving.
- A "good number" without a baseline is not evidence of response. The substrate is emphatic: "Baseline is everything. Without it, follow-up labs are meaningless numbers."
Research describes this. Track the markers. Adjust the lever, not the protocol.